IGC Announces Proposed Settlement of 3 Derivative Lawsuits & Provides Notice to Shareholders May 8, 2020 by Alejandro
IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals March 26, 2020March 27, 2020 by charlie
IGC Reports Financial Results for the Quarter Ended December 31st, 2019 February 11, 2020February 11, 2020 by charlie
IGC Announces IRB Approval of its IGC-AD1 for a Phase-2 Study September 19, 2019November 6, 2019 by Alejandro
IGC Reports Financial Results for the Quarter Ended June 30, 2019 August 8, 2019November 6, 2019 by charlie
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2019 June 14, 2019September 10, 2019 by charlie
IGC Announces Successful Appeal of Delisting Proceedings and Imminent Relisting on NYSE American February 22, 2019September 10, 2019 by charlie
IGC Announces Extension of Expiration Date and Reduction of Exercise Price of its Publicly Traded Warrants February 20, 2019September 10, 2019 by charlie
IGC Announces Financial Results for Quarter Ended December 31, 2018 February 12, 2019September 10, 2019 by charlie
